Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Publication date: Available online 11 October 2019Source: The Lancet HIVAuthor(s): Takara L Stanley, Lindsay T Fourman, Meghan N Feldpausch, Julia Purdy, Isabel Zheng, Chelsea S Pan, Julia Aepfelbacher, Colleen Buckless, Andrew Tsao, Anela Kellogg, Karen Branch, Hang Lee, Chia-Ying Liu, Kathleen E Corey, Raymond T Chung, Martin Torriani, David E Kleiner, Colleen M Hadigan, Steven K GrinspoonSummaryBackgroundNon-alcoholic fatty liver disease (NAFLD) is a substantial cause of comorbidity in people with HIV and there are no proven pharmacological treatments for the disease in this population. We assessed the effects of tesamorelin on liver fat and histology in people with HIV and NAFLD.MethodsThis randomised, double-blind, multicentre study with identical placebo as a comparator was done in a hospital and a medical research centre in the USA. People with HIV infection and a hepatic fat fraction (HFF) of 5% or more by proton magnetic resonance spectroscopy were eligible. Participants were randomly assigned (1:1) to receive either tesamorelin 2 mg once daily or placebo once daily for 12 months, followed by a 6-month open-label phase during which all participants received tesamorelin 2 mg daily. The randomisation list was prepared by the study statistician using a permuted block algorithm within each stratum with randomly varying block sizes. The primary endpoint was change in HFF between baseline and 12 months. The primary safety endpoint was glucose. Analysis was by intention to ...
Source: The Lancet HIV - Category: Infectious Diseases Source Type: research

Related Links:

Conditions:   HIV Infections;   Non-Alcoholic Fatty Liver Disease Intervention:   Drug: Semaglutide Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   The University of Texas Health Science Center, Houston Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Filomena Corbo1†, Giacomina Brunetti2*†, Pasquale Crupi3, Sara Bortolotti4, Giuseppina Storlino4, Laura Piacente5, Alessia Carocci1, Alessia Catalano1, Gualtiero Milani1, Graziana Colaianni4, Silvia Colucci2, Maria Grano4, Carlo Franchini1, Maria Lisa Clodoveo6, Gabriele D'Amato7 and Maria Felicia Faienza5 1Department of Pharmacy-Drug science, University of Bari Aldo Moro, Bari, Italy 2Section of Human Anatomy and Histology, Department of Basic and Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy 3CREA-VE, Council for Agricultural Research and Economics&ndas...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study, the gut microbiota of 30 LC patients and 30 healthy controls were examined via next-generation sequencing of 16S rRNA and analyzed for diversity and biomarkers. We found that there was no decrease in significant microbial diversity (alpha diversity) in LC patients compared to controls (P observed = 0.1422), while the composition (beta diversity) differed significantly between patients and controls (phylum [stress = 0.153], class [stress = 0.16], order [stress = 0.146], family [stress = 0.153]). Controls had a higher abundance of the bacterial phylum Actinobacteria and genus Bifidobacterium, while patients wi...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Conclusions: The lipidome is altered in ART-treated HIV infection, and may contribute to inflammation and CVD progression. Detailed lipidomic analyses may better assess CVD risk in both HIV+ and HIV– individuals than does traditional lipid profiling. Introduction Both HIV infection and the use of antiretroviral therapy (ART) contribute to an increased risk for cardiovascular disease (CVD) (1, 2). Dyslipidemia is observed in HIV-infected (HIV+) individuals, and is associated with reduced levels of high-density lipoprotein (HDL) cholesterol, and elevated total (TC) cholesterol, low-density lipoprotein (LDL) chole...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
IL-34 was recent discovered cytokine and is known ligand that binds to CSF-1 receptor, thereby enhancing tissue macrophage maturation and differentiation. Expression of IL-34 with in the lung was evident, but the localization and the expressing cells were not so far unclear. Also, M2 macrophages are known to play critical role in fibrotic disorders such as NAFLD (Non-alcoholic fatty liver disease). Therefore, we hypothesized that lung epithelial cells derived IL-34 was released and may influence lung fibrosis via M2 macrophage induction.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
In conclusion, GP73 is an effective and reliable serological marker for the diagnosis of advanced fibrosis and prediction of appearance of cirrhosis.
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
More News: Alcoholism | Allergy | Allergy & Immunology | Chia | Fatty Liver Disease (FLD) | Hospitals | Infectious Diseases | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Research | Statistics | Study | Urology & Nephrology